Mohd Ashhad: Cryoprecipitate – A Small Blood Component with a Big Clinical Role
Mohd Ashhad, Assistant at Blood bank, shared a post on LinkedIn:
“Cryoprecipitate: A Small Blood Component with a Big Clinical Role
In transfusion medicine, every blood component has a specific purpose.
Cryoprecipitate is a plasma-derived blood component that plays an important role in managing certain bleeding conditions.
What is Cryoprecipitate?
Cryoprecipitate is prepared by thawing Fresh Frozen Plasma (FFP) at cold temperatures and collecting the precipitated proteins. It is then refrozen for storage.
What does Cryoprecipitate contain?
It is rich in:
- Fibrinogen (Factor I)
- Factor VIII
- von Willebrand Factor (vWF)
- Factor XIII
- Fibronectin
When is it used?
Cryoprecipitate may be transfused when there is significant hypofibrinogenemia or dysfibrinogenemia, particularly in situations such as:
- Massive hemorrhage
- Major trauma or surgery with low fibrinogen
- Disseminated Intravascular Coagulation (DIC) with bleeding
- Certain congenital fibrinogen disorders
Important point:
Cryoprecipitate should not be used simply as a source of Factor VIII or vWF when specific factor concentrates are available and appropriate.
Its use should be guided by clinical condition and laboratory results, especially fibrinogen levels.
From donor to patient, every component matters.
Proper preparation, storage, identification, compatibility procedures, and transfusion practices are essential for patient safety.
As laboratory professionals and blood bank technologists, understanding the preparation, contents, indications, and quality requirements of cryoprecipitate is an important part of transfusion medicine.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause